Overview
- Genmab shares jumped more than 7% on Tuesday after the company and AbbVie said a phase‑3 trial of EPCORITAMAB plus R‑CHOP cut the risk of progression or death by about 51% in newly diagnosed diffuse large B‑cell lymphoma.
- The STOXX 600 rose roughly 0.8–1% for a third straight session with healthcare the strongest sector as investors pushed European equities higher on the drug trial news.
- Euro‑zone 10‑year yields pulled back from last week’s multi‑decade highs but remain sensitive to France’s effort to pass a contested 2027 budget, which earlier drove a rout in French bonds.
- The euro sat near a 17‑month low after Spanish Prime Minister Pedro Sanchez called a snap election, a political shock that has added pressure on the currency and investor sentiment.
- Traders are now watching euro‑zone retail sales, the UK S&P Global PMI and the start of third‑quarter earnings for clues on growth and rate expectations as markets scale back bets on multiple ECB hikes.